02:06 PM EDT, 08/05/2024 (MT Newswires) -- Jaguar Health ( JAGX ) Monday said it will explore ways to win additional regulatory approvals for its crofelemer antidiarrheal drug in patients with certain types of cancers, but failed to meet the primary endpoint across all tumor types.

Crofelemer currently is approved by the US Food and Drug Administration to help control diarrhea in adults on antiretroviral therapy for with HIV or AIDS. The company July 23 released results that showed meaningful improvement preventing diarrhea in patients with breast and lung cancers, but did not achieve significance in patients with all 10 of the tumor types evaluated.

The company is now planning to detail its regulatory strategy next week when it discusses its quarterly financial results.

According to Jaguar, more than 75% of the 287 patients participating in the study were being treated for some form of either breast or respiratory cancer. The company is now working with advisers to evaluate the positive outcomes for crofelemer with those subgroups and other ailments to prepare for upcoming scientific reports and future meetings with the FDA.

Price: 1.14, Change: -0.02, Percent Change: -1.72